

## Mapping Convergent and Divergent Cortical Thinning Patterns in Patients With Deficit and Nondeficit Schizophrenia

Teng Xie<sup>1–3,10</sup>, Xiangrong Zhang<sup>4,5,10</sup>, Xiaowei Tang<sup>6</sup>, Hongying Zhang<sup>7</sup>, Miao Yu<sup>5</sup>, Gaolang Gong<sup>1–3</sup>, Xiang Wang<sup>8</sup>, Alan Evans<sup>9</sup>, Zhijun Zhang<sup>5</sup>, and Yong He<sup>\*,1–3</sup>

<sup>1</sup>National Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing, China; <sup>2</sup>Beijing Key Laboratory of Brain Imaging and Connectomics, Beijing Normal University, Beijing, China; <sup>3</sup>IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China; <sup>4</sup>Department of Geriatric Psychiatry, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China; <sup>5</sup>Department of Neuropsychiatry, Affiliated ZhongDa Hospital, School of Medicine, Southeast University, Nanjing, China; <sup>6</sup>Department of Psychiatry, Wutaishan Hospital of Yangzhou, Yangzhou, China; <sup>7</sup>Department of Radiology, Subei People's Hospital of Jiangsu Province, Yangzhou University, Yangzhou, China; <sup>8</sup>Medical Psychological Institute of the Second Xiangya Hospital, Central South University, Changsha, China; <sup>9</sup>McConnell Brain Imaging Center, Montreal Neurological Institute, Montreal, Canada

<sup>10</sup>These authors contributed equally to this work.

\*To whom correspondence should be addressed; National Key Laboratory of Cognitive Neuroscience and Learning, Beijing Key Laboratory of Brain Imaging and Connectomics, IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing 100875, China. E-mail: [yong.he@bnu.edu.cn](mailto:yong.he@bnu.edu.cn)

**Deficit schizophrenia (DS) is a homogeneous subtype of schizophrenia characterized by primary and enduring negative symptoms. However, the underlying neuroanatomical substrate of DS remains poorly understood. Here, we collected high-resolution structural magnetic resonance images of 115 participants, including 33 DS patients, 41 nondeficit schizophrenia (NDS) patients, and 41 healthy controls (HCs), and calculated the cortical thickness and surface area for statistical comparisons among the 3 groups. Relative to the control group, both the DS and NDS groups exhibited convergent cortical thinning in the bilateral inferior frontal gyri and the left superior temporal gyrus. The cortical thinning in the right inferior frontal cortex in the patient group was significantly positively correlated with declines of cognitive flexibility and visuospatial memory. Importantly, compared to the NDS group, the DS group exhibited a more widespread cortical thinning pattern, with the most significant differences in the left temporo-parietal junction area. For the surface area measurement, no significant group differences were observed. Collectively, these results highlight the convergent and divergent cortical thinning patterns between patients with DS and NDS, which provide critical insights into the neuroanatomical substrate of DS and improve our understanding of the biological mechanism that contributes to the negative symptoms and cognitive impairments in DS.**

**Keywords:** deficit schizophrenia/MRI/cortical thickness/surface area/temporo-parietal junction

### Introduction

Deficit schizophrenia (DS) is a homogeneous subtype of schizophrenia, which is characterized by primary and enduring negative symptoms and impaired social function and emotional processing.<sup>1</sup> Elucidating whether neuroanatomical substrates in DS differ from those in nondeficit schizophrenia (NDS) is critical for the facilitation of biomarker discovery in this disease.

Structural MRI provides a promising avenue to quantitatively describe the neuroanatomical features of the brain. For example, several cross-sectional studies have documented that the negative symptoms in schizophrenia are associated with volumetric measures in specific parts of the brain, including the gray matter (GM) in the entire frontal cortex,<sup>2</sup> the ventro-medial prefrontal cortex,<sup>3</sup> and the temporal lobe<sup>4</sup> and the white matter in the prefrontal cortex.<sup>5</sup> Longitudinal studies have revealed that an accelerating reduction in frontal lobe GM and white matter volumes, an increase in the frontal lobe cerebrospinal fluid (CSF) volume,<sup>6,7</sup> and progressive reduction in temporal lobe GM volume<sup>6</sup> are correlated with greater negative symptom severity. There is also evidence of a relationship between negative symptoms and the GM thickness of the left orbitofrontal cortex in schizophrenia.<sup>8</sup> These findings regarding the relationship between negative symptoms and morphological measurements raise the possibility that DS patients who exhibit higher levels of negative symptoms are likely to suffer

more severe neuroanatomical abnormalities than NDS patients without the predominant features of lasting negative symptoms.

To date, several structural MRI studies have directly examined the neuroanatomical differences between DS and NDS, primarily focusing on volumetric analyses and producing discordant findings. For example, nonsignificant differences were observed between the DS and NDS groups in several global measures such as the total brain volume, the total volume of the ventricles,<sup>9</sup> the total GM volume, the total white matter volume and the total CSF volume.<sup>10</sup> However, significant volumetric differences in specific GM regions were observed. For example, DS patients exhibited significant volumetric reductions in the superior frontal gyrus,<sup>11,12</sup> superior and middle temporal gyrus,<sup>11–13</sup> the left anterior cingulate and the right putamen<sup>11</sup> compared with the volumes in the NDS patients. Conversely, NDS patients showed a greater volumetric reduction in the dorsal lateral prefrontal cortex than DS patients.<sup>14</sup> These conflicting findings could be associated with insensitive GM volumetric measurements, leading to an imprecise understanding of the neuroanatomical characteristics of DS and NDS.

It is worth noting that the cortical GM volume is the product of two morphological indices: cortical thickness and surface area. Beyond the abovementioned volume-based analyses, these 2 surface-based measurements allow us to obtain more detailed information regarding the alterations of cortical structures observed in schizophrenia. Specifically, it is assumed that the cortical thickness has greater etiological relevance for schizophrenia than that of GM volume or density.<sup>15</sup> While the cortical thickness reveals the number, size, and arrangement of the cells within a column, the surface area is more related to the number of columns within a certain cortical region.<sup>16–18</sup> Previous structural imaging studies have shown that these 2 surface-based characteristics of the brain were associated with schizophrenia<sup>19</sup> and negative symptoms.<sup>8,20</sup> To date, only 2 studies have explored the patterns of cortical thickness and surface area in DS and NDS patients.<sup>21,22</sup> Neither of these studies reported significant differences in surface area between 2 patient groups, or between either patient group and the healthy controls (HCs). With regard to the cortical thickness, Takayanagi et al<sup>21</sup> exclusively examined the mean thickness of the anterior cingulate gyrus using a region of interest (ROI) approach and observed significant thinning in this region in the DS group as compared with that in the NDS groups. Voineskos and colleagues<sup>22</sup> reported that compared with HCs, both DS and NDS patients showed cortical thinning in the several frontal and temporal regions, but no significant differences between the 2 patient groups. They speculated that cortical thinning might serve as a common neuroanatomical feature in patient with schizophrenia, regardless of the 2 clinical subtypes. Thus, it remains to be elucidated whether patients with DS differ from patients

with NDS in neuroanatomical measures of cortical morphology such as surface area and cortical thickness.

To address this issue, we examined cortical thickness and surface area measures in a large structural MRI dataset that included 115 participants (33 DS, 41 NDS, and 41 HCs). Given the aforementioned substantial clinical heterogeneity and morphological differences between DS and NDS, we hypothesized that patients with the 2 subtypes of schizophrenia would exhibit convergent and divergent neuroanatomical abnormalities in the frontal and temporal regions and that these structural abnormalities would correlate with cognitive performance. These comparisons might help to clarify the commonalities and differences between the neurobiological characteristics of DS and NDS patients.

## Methods

### Subjects

A total of 128 males participated in this study, including 84 clinically stable schizophrenia patients (40 DS and 44 NDS) and 44 HCs. The patients were recruited from the psychiatric rehabilitation unit of Yangzhou Wutaishan Hospital, Jiangsu Province, China. The patients' eligibility criteria included: (1) a diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and confirmed by the Chinese version of the Structured Clinical Interview for DSM-IV (SCID-I)<sup>23</sup>; (2) right-handed Chinese Han patients between the ages of 20 and 65 years; and (3) having stable psychiatric symptoms and treatment with antipsychotic medications for at least 12 months based on their medical records. The exclusion criteria for the patients included severe comorbid conditions, such as neurological disorders, head trauma, mental retardation, alcoholism or substance abuse, and a history of previous electroconvulsive therapy. The diagnoses of DS and NDS were determined according to the Chinese version of the schedule for the deficit syndrome (SDS).<sup>24</sup> The SDS rates the deficit syndrome as present if 2 of the following symptoms are at least moderately severe, persistent over 12 months and not attributable to secondary sources (eg, medication side effects, depression, paranoia, and anxiety): restricted affect, diminished emotional range, poverty of speech, curbing of interests, diminished sense of purpose, and diminished social drive. The SDS scale is also organized into 2 factors (factor 1, avolition and factor 2, poor emotional expression) based on previous studies.<sup>25,26</sup> The HCs were matched for age and handedness with the patients, were recruited from the local community, and met the following criteria: (1) no lifetime history of psychotic, mood, or substance abuse or dependence, as ascertained by the Structured Clinical Interview for DSM-IV Non-Patient version (SCID-NP)<sup>27</sup>; (2) no history of organic brain disorders, mental retardation, or severe head trauma; and (3) no family history of psychiatric disorders. The data

from 13 subjects were excluded due to head motion during the scan (7 DS, 2 NDS, and 1 HC) and imaging processing failures (1 NDS and 2 HC). Lastly, the data from the remaining 115 participants (33 DS, 41 NDS, and 41 HCs) were included in the final analysis. The study was approved by the Institutional Ethical Committee for clinical research of Zhongda Hospital Affiliated to Southeast University. Written informed consent was obtained from each participant.

### Clinical Evaluation

The severity of the schizophrenic symptoms was evaluated by the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative Symptoms (SANS), and the Scale for the Assessment of Positive Symptoms (SAPS). The BPRS scale is organized into positive, negative, disorganized, and affect syndromes based on the findings of the most comprehensive factor analysis of the 18-item BPRS.<sup>28,29</sup> Table 1 illustrates the clinical and demographic data of all participants.

### Neurocognitive Assessments

For each participant, we performed a battery of classical neuropsychological tests, including the Digit Vigilance Test (DVT), the Animal Naming Test (ANT), the Controlled Oral Word Association Test (COWAT), the Block Design Test in Wechsler Adult Intelligence Scale-Chinese Revision (WAIS-RC), the Trail Making Test-A, B (TMT-A,B), the Stroop Color-Word Test (SCWT), and the Spatial Processing Test (Block Design). Based on previous reports regarding the cognitive processes assessed by each test,<sup>30-34</sup> these variables were further grouped

into 4 rationally motivated domains: sustained vigilance/attention (hereinafter labeled sustained attention with 4 tests: DVT, TMT-A, Stroop colors, and Stroop words), cognitive flexibility (2 tests: TMT-B and Stroop interference), ideation fluency (2 tests: ANT and COWAT), and visuospatial memory (2 tests: Spatial Processing, Block Design and WAIS-RC). For each cognitive domain, a composite score analysis was conducted as follows.<sup>30,34,35</sup> Briefly, for each patient the standardized Z score of each cognitive test was calculated based on the corresponding neurocognitive data of the control group. The composite scores in the cognitive domain were then calculated by summing the Z-transformed scores of all of the neuropsychological tests within the domain. The data reduction of the neurocognitive measures avoids multiple comparisons and corrects the interdependency between the neuropsychological measures.<sup>30,34,35</sup> Notably, some variables (eg, TMT), in which low values indicated good performance, were adjusted for sign to ensure that higher Z-scores represented better performance for all variables. Thus, for each patient, we obtained 4 composite scores representing performance in the 4 cognitive domains. Finally, Cronbach's alpha and Cohen's *d* effect sizes<sup>36,37</sup> were computed for each cognitive domain. Table 2 presented the neurocognitive data of the 3 groups.

### Image Acquisition and Processing

Structural MRI data were acquired with a high-resolution 3D magnetization prepared rapid acquisition gradient echo sequences (for details, see supplementary information). We used the CIVET pipeline (version 1.1.9.<sup>38</sup>) to measure the cortical thickness and surface area in the brain. Briefly, the native MR images were first registered into stereotaxic

**Table 1.** Demographics and Clinical Characteristics for DS, NDS, and HC Groups

	DS (n = 33)	NDS (n = 41)	HC (n = 41)	F/ $\chi^2$ /t	P-Value
Age (years)	49.03 ± 7.67	45.71 ± 6.64	45.78 ± 9.48	1.97	.145
Education (years)	8.82 ± 2.02 <sup>Δ</sup>	9.12 ± 1.82 <sup>Δ</sup>	10.54 ± 2.72	6.51	.002
Age at onset (years)	22.03 ± 2.81	22.39 ± 2.66		-0.56	.575
Duration of illness (years)	27.00 ± 6.92*	23.32 ± 6.88		2.28	.025
BPRS total	31.67 ± 2.97**	27.56 ± 2.65		6.29	<.001
Positive syndrome	6.00 ± 1.06	6.41 ± 1.05		-1.68	.097
Negative syndrome	12.33 ± 1.67**	7.46 ± 1.00		14.74	<.001
Disorganized syndrome	6.55 ± 1.37	6.46 ± 0.84		0.32	.752
Affect	6.79 ± 1.19	7.22 ± 1.31		-1.46	.148
SANS total	56.97 ± 8.47**	31.98 ± 6.11		14.73	<.001
SAPS total	8.67 ± 3.76	10.17 ± 4.24		-1.60	.115
SDS total score	11.06 ± 2.52**	4.07 ± 2.42		12.11	<.001
Avolition	5.94 ± 1.56**	2.54 ± 1.52		9.47	<.001
Poor emotional expression	5.12 ± 1.27**	1.54 ± 1.12		12.90	<.001
Smoking ratio (%)	63.60	75.60		1.26	.263
CPZ-equivalent daily dosage (mg/day)	467.73 ± 234.98	527.80 ± 208.14		-1.17	.248

Note: DS, deficit schizophrenia; NDS, nondeficit schizophrenia; HC, healthy controls; BPRS, Brief Psychiatric Rating Scale; SANS, the Scale for the Assessment of Negative Symptoms; SAPS, the Scale for the Assessment of Positive Symptoms; SDS: the Schedule for the Deficit Syndrome; CPZ, chlorpromazine; \*Vs NDS, *P* < .05; \*\*Vs NDS, *P* < .001; <sup>Δ</sup>Vs HC, *P* < .05.

**Table 2.** Comparisons of Neurocognitive Domains and Raw Neuropsychological Performance Among DS, NDS, and HC Groups

	DS ( <i>n</i> = 33)	NDS ( <i>n</i> = 41)	HC ( <i>n</i> = 41)	<i>F</i>	<i>P</i> -Value	Cronbach's Alpha
Sustained vigilance/attention	-11.02 ± 6.86	-4.04 ± 3.28	—	—	—	0.789
Digit vigilance test (s)	312.36 ± 161.02** <sup>△△</sup>	178.31 ± 66.76	137.82 ± 42.34	24.54	<.001	—
TMT-A (seconds)	132.95 ± 67.68** <sup>△△</sup>	81.80 ± 30.95 <sup>△</sup>	49.31 ± 22.87	27.52	<.001	—
Stroop words only	42.70 ± 18.93** <sup>△△</sup>	59.07 ± 16.09 <sup>△△</sup>	79.15 ± 16.79	33.66	<.001	—
Stroop colors only	26.79 ± 12.63** <sup>△△</sup>	35.20 ± 11.14 <sup>△△</sup>	49.32 ± 13.26	22.92	<.001	—
Ideation fluency	-3.44 ± 1.82	-2.03 ± 2.09	—	—	—	0.669
COWAT	4.88 ± 3.16* <sup>△△</sup>	6.76 ± 3.51 <sup>△</sup>	9.17 ± 2.33	14.20	<.001	—
Animal naming test	9.73 ± 3.47* <sup>△△</sup>	12.46 ± 4.46 <sup>△△</sup>	18.41 ± 4.60	33.15	<.001	—
Cognitive flexibility	-4.12 ± 2.59	-2.08 ± 1.37	—	—	—	0.725
TMT-B (s)	304.05 ± 119.44** <sup>△△</sup>	199.09 ± 53.33 <sup>△△</sup>	123.57 ± 63.47	35.97	<.001	—
Stroop interference	17.42 ± 11.08 <sup>△△</sup>	21.34 ± 8.81 <sup>△△</sup>	32.32 ± 10.58	15.92	<.001	—
Visuospatial memory	-3.72 ± 2.00	-2.11 ± 1.42	—	—	—	0.681
Spatial processing (block design)	11.24 ± 4.39* <sup>△△</sup>	13.41 ± 3.35 <sup>△△</sup>	18.02 ± 3.46	24.16	<.001	—
WAIS-RC (block design)	13.55 ± 8.87** <sup>△△</sup>	21.41 ± 6.55 <sup>△</sup>	27.73 ± 8.27	21.98	<.001	—

*Note:* Patients' neuropsychological test scores were standardized using the healthy control (HC) group data. Sustained vigilance/attention domain includes Stroop words only and colors only, Trail making test part A and Digit vigilance test. Ideation fluency domain includes Controlled Oral Word Association test and Animal Naming Test. Cognitive flexibility includes Stroop color/word interference test and Trail making test part B. Visuospatial memory domain includes Spatial processing test and Wechsler adult intelligence scale (Block Design, Chinese version). DS, deficit schizophrenia; NDS, non-deficit schizophrenia. \*Vs NDS, *P* < .05; \*\*Vs NDS, *P* < .001; <sup>△</sup>Vs HC, *P* < .05; <sup>△△</sup>Vs HC, *P* < .001.

space<sup>39</sup> using a 9-parameter linear transformation.<sup>40</sup> Simultaneously, the images were corrected for nonuniformity artifacts using the N3 algorithms.<sup>41</sup> The registered and corrected images were further segmented into GM, white matter, CSF, and background using an advanced neural net classifier.<sup>38</sup> The inner and outer GM surfaces were then automatically extracted from each MR volume using the constrained Laplacian-based automated segmentation with proximities algorithm<sup>42,43</sup> and the cortical thickness was measured in native space using the linked distance between the 2 surfaces at 81 924 vertices (40962 on each hemisphere) throughout the cortex. The measurement in native space provided an unadjusted estimate of the absolute cortical thickness.<sup>44</sup> Smoothing with 20 mm kernel was then applied to improve sensitivity.<sup>45</sup> The cortical thickness algorithm was validated using both manual measurements<sup>46</sup> and simulation approaches.<sup>47,48</sup> The surface area was evaluated on a mid-surface, represented as a polyhedral mesh lying right in the middle of the inner and outer GM surfaces. The surface area on each vertex was defined as a third of the total area of all the triangles adjoining to it, then smoothed with a 20 mm kernel. The surface area of a brain region was the sum of all the vertices belonging to it.

### Statistics

The continuous and categorical variables were analyzed using the general linear model (GLM) and the chi-square test, respectively. Comparisons of clinical symptoms between the DS and NDS groups were conducted using 2 sample *t*-tests. The differences of composite scores of

each cognitive domain between the 2 patient subgroups were evaluated using effect size estimation (Cohen's *d*). For all analyses, the significance level was set to *P* < .05.

To detect cortical thickness differences among the 3 groups, we performed the GLM analysis with age and education as covariates at 3 scales: the mean thickness, vertex-based, and an ROI-based thickness analysis based on the automated anatomical labeling atlas. For the group main effects from either the vertex-based or ROI-based GLM analyses, a false discovery rate (FDR) correction was implemented to correct for multiple comparisons.<sup>49</sup> Three contrast tests (DS vs HC, NDS vs HC, and DS vs NDS) based on the same model were performed to determine between-group differences. An FDR correction was applied in which the *P*-values from all 3 comparisons were pooled together. The *q*-value was set to .05. A cluster size threshold of 30 vertices was then applied to further reduce false positive clusters. To remove the effects of illness duration and medication dose in the patient groups, we applied another GLM to the DS and NDS groups with illness duration and medication dose as additional covariates, followed with an FDR correction at *q*-value = .05. All the cortical thickness comparisons were conducted using SurfStat toolbox (<http://www.math.mcgill.ca/keith/surfstat/>, Accessed November 12, 2017) and the results were visualized using the BrainNet Viewer toolbox.<sup>50</sup> For the surface area measurements, the statistical comparisons were the same as those for the cortical thickness analysis.

To determine brain-cognitive/clinical relationship, we performed the GLM analyses using the GRETNA toolbox.<sup>51</sup> For the overlapping regions with significant

abnormalities shared by the 2 patient groups, we estimated the relationship across all patients. For the regions that differed between the DS and NDS groups, we separately estimated the brain-cognition/clinical (including 2 factors of the SANS: diminished expression and social amotivation) relationships in each group. Age, education, illness duration, and medication dose were taken as covariates. For details, see supplementary materials.

## Results

### *Demographic and Clinical Characteristics*

Among the 3 groups, the differences in education ( $P = .002$ ), but not age ( $P = .145$ ), were significant (Table 1). Least-significant difference post hoc comparisons revealed lower education levels in both the DS ( $P = .001$ ) and NDS ( $P = .005$ ) patients relative to the HCs, whereas the 2 patient subgroups did not differ significantly ( $P = .562$ ). The DS patients exhibited a longer illness duration ( $P = .025$ ) and more severe psychopathological total symptoms and negative symptoms (all  $P < .001$ ) than the NDS patients. For the types of antipsychotic drugs, there was no significant difference between the DS and NDS groups ( $\chi^2[2] = 1.163$ ,  $P = .559$ ) (conventional antipsychotics: 48.5% [ $n = 16$ ] and 36.6% [ $n = 15$ ]; novel antipsychotics: 30.3% [ $n = 10$ ] and 34.1% [ $n = 14$ ]; combination: 21.2% [ $n = 7$ ] and 29.3% [ $n = 12$ ], respectively). The mean age of onset, smoking, antipsychotic medication dose (chlorpromazine equivalents), the positive, affect, and disorganized syndromes did not differ significantly between the 2 patient subgroups.

### *Cognitive Characteristics*

For each neuropsychological test, we observed significant differences among the 3 groups with age and education as covariates (all  $P < .001$ , table 2). Least-significant difference post hoc comparisons indicated that both of the patient groups performed significantly worse than the control group on most of the neuropsychological tests (all  $P < .05$ , except the DVT for NDS vs HC,  $P = .129$ ). Moreover, the DS group performed significantly worse than the NDS group on most neuropsychological measures (all  $P < .05$ , except the Stroop interference for DS vs NDS,  $P = .346$ ). Cronbach's alpha ranged from 0.669 to 0.789 in the 4 cognitive domains, indicating relatively high internal consistency among the measures. The Cohen's  $d$  effect size ranged from 0.720 to 1.298 in the 4 cognitive domains, indicating that the DS–NDS differences in cognitive performance achieved moderate to large effect sizes.

### *Cortical Thickness Comparisons*

The mean cortical thickness in the whole cortex differed significantly among the 3 groups ( $P = .02$ ), with significantly thinner cortices in the DS group than the HC group ( $P < .005$ ) and nonsignificant differences between

the NDS and HC groups or between the DS and NDS groups ( $P = .16$  and  $.10$ , respectively). The total surface area did not differ significantly among the 3 groups ( $P = .26$ ).

The vertex-based analyses revealed the main effects of group ( $q = .05$ , FDR-corrected, figure 1A), which was primarily distributed in the bilateral superior temporal gyri, the bilateral middle temporal gyri, the bilateral inferior frontal gyri, the left Heschl gyrus, the left supramarginal gyrus, and the left angular gyrus. Further post hoc analyses revealed that, compared with the HC group, the DS group exhibited widespread cortical thinning, with patterns similar to those observed for the main effects of group and the NDS patients had thinner cortices in the bilateral inferior frontal gyri and the left superior temporal areas (supplementary figure S1). Thus, compared to the HC group, the 2 schizophrenia subgroups exhibited shared cortical thinning in the bilateral inferior frontal gyrus and the left anterior superior temporal gyrus (figure 2, middle row). Notably, the DS group showed significant cortical thinning in the left temporo-parietal junction (TPJ) (including the angular gyrus, the supramarginal gyrus, and the posterior superior temporal gyrus<sup>52</sup>) as compared to the NDS group (Figure 3). The differences of the TPJ area remained significant after removing the effects of 4 cognitive domain scores and clinical evaluations (SAPS, BPRS total score or the positive syndrome, disorganized syndrome, and affect subscales of BPRS). Finally, the ROI-based analyses results were approximately the same as the vertex-analyses results (Figure 1B; supplementary figure S2 and table S1).

### *Surface Area Comparisons*


The surface area analysis did not reveal any significant difference among the 3 groups after FDR correction.

### *Correlation Between Cognitive/Clinical Variables and the Morphological Measurements*

We observed that the mean cortical thickness of the largest overlapping cluster, which was located in the right inferior frontal gyrus, was positively correlated with cognitive flexibility ( $P = .0018$ ) and visuospatial memory performance ( $P = .00006$ ) (figure 2, bottom row). For the SANS, we only found a trend toward negative correlation between the TPJ thickness and the social amotivation factor ( $P = .09$ ) in the DS group.

## Discussion

The present study explored the cortical abnormalities of patients with DS and NDS as well as the relationship between cortical thickness and cognitive performance. Relative to HCs, both patient groups demonstrated common cortical thinning in the bilateral inferior frontal and the left superior temporal regions. We also provided the




**Fig. 1.** Main effects of group on the cortical thickness (FDR corrected,  $q < .05$ ). (A) Regions differed among the 3 groups on the vertex level. (B) Regions differed among the 3 groups on the region of interest level.

first evidence illustrating that the cortical thinning in the left TPJ is a salient feature in DS as compared with NDS.

We observed that the bilateral inferior frontal and left superior temporal areas were overlapped regions showing significant cortical thinning in both of the DS and NDS subgroups relative to the HC subjects. Our findings are in agreement with previous morphological studies revealing cortical thinning in the orbitofrontal, inferior frontal,<sup>8,53-61</sup> and the superior temporal regions<sup>17,53,56-58,62-64</sup> in schizophrenia. A previous study of cortical thickness in DS and NDS found that the patient groups shared nearly the same cortical thinning pattern, involving the bilateral temporal and inferior frontal areas, which is similar to our results.<sup>22</sup> Volumetric studies of DS and NDS patients also identified the frontal and temporal lobes as regions preferentially affected by the 2 subtypes of schizophrenia.<sup>10-14,65</sup> Considering that the current study and other surface-based studies comparing patients with DS and NDS and HCs<sup>21,22</sup> did not find any significant difference in surface area, cortical thickness measurement may play a vital role in describing neuroanatomical signatures in schizophrenia of different subtypes. Rimol and colleagues also demonstrated that cortical thinning rather than surface contraction mainly drives the volume reductions in schizophrenia.<sup>19</sup> Cortical thickness and surface area reveal different neurophysiological information,<sup>16-18</sup> have distinct genetic origins<sup>66,67</sup> and different developmental trajectories.<sup>68-70</sup> These 2 relatively independent structural features of the cortex may respond differently to the undergoing pathological process of schizophrenia, which might account for their different capabilities in

revealing the structural changes related to the disease. In this study, the thickness in the right orbital frontal region positively correlated with cognitive flexibility and visuospatial memory performance. Intriguingly, a previous study found correlation between the GM density in the right inferior frontal region and the cognitive flexibility.<sup>71</sup> Another study demonstrated an activation in the right orbitofrontal area in the process of memory formation.<sup>72</sup> Our findings implied that the cortical thinning in the inferior frontal and the superior temporal regions are a common feature of the clinical syndrome of schizophrenia and may contribute to the cognitive impairments, regardless of different subtypes of the disease.


Importantly, we showed distinct cortical thinning patterns in the left TPJ between DS and NDS patients. Different from our findings, Voineskos et al<sup>22</sup> did not report significant differences when they directly compared the cortical thickness between DS and NDS patients. This result discrepancy between the previous work and our study might be due to several methodological differences: the magnetic field strength of the MRI scanning (1.5T vs 3.0T), the criteria classifying DS/NDS patients (PDS [the proxy for the deficit syndrome] vs SDS) and the composition of subjects (gender [14 males and 4 females for each group vs all male participants] and ethnicities [both Caucasians and non-Caucasians vs Chinese]). Although still controversial, it has been previously reported that DS patients exhibit decreased temporal GM volumes<sup>11,12</sup> and an increased left temporal CSF volume,<sup>4</sup> compared with NDS patients. Previous studies also demonstrated that schizophrenia patients with more severe negative



**Fig. 2.** Regions showing common cortical thinning in the 2 patient groups comparing with the healthy control on the vertex level (false discovery rate corrected,  $q < .05$ ). Box-plots on the top showed the distribution of mean thickness within corresponding cluster. The bottom shows the correlation between the mean thickness of the right inferior frontal region and cognitive flexibility and visuospatial memory scores. Red circles and blue triangles referred to deficit schizophrenia and nondeficit schizophrenia patients, respectively.

symptoms suffered more severe brain atrophy in the left temporal lobe,<sup>4,6</sup> which provided further support for our result. One particularly interesting finding here was that the cortical reduction was apparent predominantly in the left TPJ. Notably, the TPJ is a critical region of the theory of mind (ToM), a social cognitive construct referring to “the ability to make inference upon one’s own and other

persons’ mental states.”<sup>73</sup> It has been shown previously that compared to HCs, activation in left TPJ is abnormal in schizophrenia patients during various ToM tasks.<sup>74-83</sup> Previous studies have also demonstrated an association between performance in ToM tasks and the severity of negative symptoms.<sup>84-89</sup> These findings implied that the dysfunction of the left TPJ may be more related to the



**Fig. 3.** Regions showing cortical thinning in deficit schizophrenia than nondeficit schizophrenia groups on the vertex level (false discovery rate corrected,  $q < .05$ ).

deficit type of schizophrenia. There are also evidences showing the involvement of the left TPJ in various processes such as eye gaze perception and representation<sup>90</sup> and affective prosody perception.<sup>91</sup> Cortical thickness abnormalities in the left TPJ might interfere these functions and result in difficulties in social activities, which was supported by our finding of a negative association trend between the TPJ thickness and the social amotivation factor of SANS in the DS group. Furthermore, a more severe TPJ (the angular gyrus and the supramarginal gyrus) hypometabolism was also observed in DS than in NDS patients.<sup>92</sup> Finally, transcranial magnetic stimulation on the left TPJ area could alleviate negative symptoms of schizophrenia patients.<sup>93</sup> In summary, our results suggest that the cortical thickness abnormalities in TPJ were related to the negative symptoms but not to the cognitive impairments in DS patients. The biological mechanisms underlying these structural abnormalities remain to be further explored.

The present study has several methodological limitations. First, the patients were all chronic male inpatients. Thus, our results might be contaminated by the influences of antipsychotic medication exposure and limited living environment. Nonetheless, this patient cohort is highly homogenous regarding aspects such as gender and social environment, thus might facilitate the finding of reliable cortical alterations between the 2 patient groups by restricting the variance due to confounders. Future studies should consider collecting larger dataset including female subjects and outpatients. Second, cortical thickness and surface area were selected as morphological measurements, eliminating the possibility of investigating subcortical regions. Volume reductions in the hippocampus and the thalamus have been found in DS patients relative to the HCs and NDS patients,<sup>11,65</sup> implying an association between subcortical regions and negative symptoms. Taking measurements of the subcortical cortex into consideration may help us understand the emergence of negative symptoms, particularly those related to emotional and motivational features. Furthermore, it has been found that fractional anisotropy is reduced in the left uncinate fasciculus of DS patients but not NDS

patients.<sup>22,94</sup> These findings indicate that DS patients with the primary negative symptoms might show abnormal brain connectivity, which needs to be explored in the future. Finally, the current study lacked social cognitive tests. Future studies with more comprehensive cognitive evaluations would help understanding the brain–cognition relationship in patients with DS and NDS.

### Supplementary Material

Supplementary data are available at *Schizophrenia Bulletin* online.

### Funding

This study was supported by the National Natural Science Foundation of China (81620108016, 91432115, 81571314, and 81371474), the National Key Research and Development Program (2016YFC1307000), the Beijing Natural Science Foundation (Z161100004916027, Z161100000216152, and Z151100003915082), the Fundamental Research Funds for the Central Universities (2015KJJCA13 and 2017XTCX04), Nanjing Technology Development Foundation (201505001), and the Six Talent Peaks Project in Jiangsu Province (2015-WSN-071).

### Acknowledgment

The authors declared no conflicts of interest.

### References

1. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. *Am J Psychiatry*. 1988;145:578–583.
2. Wible CG, Anderson J, Shenton ME, et al. Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study. *Psychiatry Res*. 2001;108:65–78.
3. Chua SE, Wright IC, Poline JB, et al. Grey matter correlates of syndromes in schizophrenia. A semi-automated analysis of structural magnetic resonance images. *Br J Psychiatry*. 1997;170:406–410.
4. Turetsky B, Cowell PE, Gur RC, Grossman RI, Shtasel DL, Gur RE. Frontal and temporal lobe brain volumes in schizophrenia: relationship to symptoms and clinical subtype. *Arch Gen Psychiatry*. 1995;52:1061–1070.
5. Sanfilippo M, Lafargue T, Rusinek H, et al. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. *Arch Gen Psychiatry*. 2000;57:471–480.
6. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. *Arch Gen Psychiatry*. 2001;58:148–157.
7. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. *Arch Gen Psychiatry*. 2003;60:585–594.

8. Venkatasubramanian G, Jayakumar PN, Gangadhar BN, Keshavan MS. Automated MRI parcellation study of regional volume and thickness of prefrontal cortex (PFC) in antipsychotic-naïve schizophrenia. *Acta Psychiatr Scand*. 2008;117:420–431.
9. Arango C, McMahon RP, Lefkowitz DM, Pearlson G, Kirkpatrick B, Buchanan RW. Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. *Psychiatry Res*. 2008;162:91–100.
10. Quarantelli M, Larobina M, Volpe U, et al. Stereotaxy-based regional brain volumetry applied to segmented MRI: validation and results in deficit and nondeficit schizophrenia. *Neuroimage*. 2002;17:373–384.
11. Cascella NG, Fieldstone SC, Rao VA, Pearlson GD, Sawa A, Schretlen DJ. Gray-matter abnormalities in deficit schizophrenia. *Schizophr Res*. 2010;120:63–70.
12. Fischer BA, Keller WR, Arango C, et al. Cortical structural abnormalities in deficit versus nondeficit schizophrenia. *Schizophr Res*. 2012;136:51–54.
13. Galderisi S, Quarantelli M, Volpe U, et al. Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. *Schizophr Bull*. 2008;34:393–401.
14. Volpe U, Mucci A, Quarantelli M, Galderisi S, Maj M. Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012;37:264–269.
15. Ehrlich S, Brauns S, Yendiki A, et al. Associations of cortical thickness and cognition in patients with schizophrenia and healthy controls. *Schizophr Bull*. 2012;38:1050–1062.
16. Rakic P. Defects of neuronal migration and the pathogenesis of cortical malformations. *Prog Brain Res*. 1988;73:15–37.
17. Narr KL, Bilder RM, Toga AW, et al. Mapping cortical thickness and gray matter concentration in first episode schizophrenia. *Cereb Cortex*. 2005;15:708–719.
18. Mountcastle VB. Modality and topographic properties of single neurons of cat's somatic sensory cortex. *J Neurophysiol*. 1957;20:408–434.
19. Rimol LM, Nesvåg R, Hagler DJ Jr, et al. Cortical volume, surface area, and thickness in schizophrenia and bipolar disorder. *Biol Psychiatry*. 2012;71:552–560.
20. Padmanabhan JL, Tandon N, Haller CS, et al. Correlations between brain structure and symptom dimensions of psychosis in schizophrenia, schizoaffective, and psychotic bipolar I disorders. *Schizophr Bull*. 2015;41:154–162.
21. Takayanagi M, Wentz J, Takayanagi Y, et al. Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia. *Schizophr Res*. 2013;150:484–490.
22. Voineskos AN, Foussias G, Lerch J, et al. Neuroimaging evidence for the deficit subtype of schizophrenia. *JAMA Psychiatry*. 2013;70:472–480.
23. First MB, Gibbons M, Spitzer RL, Williams, JBW. *Users Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders-Research Version (SCID-I, Version 2.0, February 1996 Final Version)*. New York: Biometrics Research Department; 1996.
24. Wang X, Yao S, Kirkpatrick B, Shi C, Yi J. Psychopathology and neuropsychological impairments in deficit and nondeficit schizophrenia of Chinese origin. *Psychiatry Res*. 2008;158:195–205.
25. Kimhy D, Yale S, Goetz RR, McFarr LM, Malaspina D. The factorial structure of the schedule for the deficit syndrome in schizophrenia. *Schizophr Bull*. 2006;32:274–278.
26. Nakaya M, Ohmori K. A two-factor structure for the Schedule for the Deficit Syndrome in schizophrenia. *Psychiatry Res*. 2008;158:256–259.
27. First MB, Spitzer RL, Gibbon M, Williams JBW. *Structured Clinical Interview for DSM-IV Axis I Disorders: Non-patient Edition (SCID-NP)*. New York: Biometrics Research Department; 1996.
28. Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW. Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. *Schizophr Bull*. 2007;33:1201–1212.
29. Mueser KT, Curran PJ, McHugo GJ. Factor structure of the Brief Psychiatric Rating Scale in schizophrenia. *Psychol Assess*. 1997;9:196–204.
30. Jaeger J, Czobor P, Berns SM. Basic neuropsychological dimensions in schizophrenia. *Schizophr Res*. 2003;65:105–116.
31. Kelland DZ, Lewis RF. The digit vigilance test: reliability, validity, and sensitivity to diazepam. *Arch Clin Neuropsychol*. 1996;11:339–344.
32. Schretlen DJ, Cascella NG, Meyer SM, et al. Neuropsychological functioning in bipolar disorder and schizophrenia. *Biol Psychiatry*. 2007;62:179–186.
33. Dickinson D, Ragland JD, Gold JM, Gur RC. General and specific cognitive deficits in schizophrenia: Goliath defeats David? *Biol Psychiatry*. 2008;64:823–827.
34. Réthelyi JM, Czobor P, Polgár P, et al. General and domain-specific neurocognitive impairments in deficit and nondeficit schizophrenia. *Eur Arch Psychiatry Clin Neurosci*. 2012;262:107–115.
35. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. *Am J Psychiatry*. 2002;159:1018–1028.
36. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*: Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
37. Rosnow NJ, Rosenthal R. Computing contrasts, effect sizes, and counterfactuals on other people's published data: general procedures for research consumers. *Psychol Methods*. 1996;1:331–340.
38. Zijdenbos AP, Forghani R, Evans AC. Automatic “pipeline” analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. *IEEE Trans Med Imaging*. 2002;21:1280–1291.
39. Talairach J, Tournoux P. *Co-planar Stereotaxic Atlas of the Human Brain: 3-dimensional Proportional System: An Approach to Cerebral Imaging*: Stuttgart; New York; New York: G. Thieme; Thieme Medical Publishers; 1988.
40. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. *J Comput Assist Tomogr*. 1994;18:192–205.
41. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. *IEEE Trans Med Imaging*. 1998;17:87–97.
42. MacDonald D, Kabani N, Avis D, Evans AC. Automated 3-D extraction of inner and outer surfaces of cerebral cortex from MRI. *Neuroimage*. 2000;12:340–356.
43. Kim JS, Singh V, Lee JK, et al. Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classification. *Neuroimage*. 2005;27:210–221.

44. Shaw P, Greenstein D, Lerch J, et al. Intellectual ability and cortical development in children and adolescents. *Nature*. 2006;440:676–679.
45. Chung MK, Worsley KJ, Robbins S, et al. Deformation-based surface morphometry applied to gray matter deformation. *Neuroimage*. 2003;18:198–213.
46. Kabani N, Le Goualher G, MacDonald D, Evans AC. Measurement of cortical thickness using an automated 3-D algorithm: a validation study. *Neuroimage*. 2001;13:375–380.
47. Lerch JP, Evans AC. Cortical thickness analysis examined through power analysis and a population simulation. *Neuroimage*. 2005;24:163–173.
48. Lee J, Lee JM, Kim JH, Kim IY, Evans AC, Kim SI. A novel quantitative validation of the cortical surface reconstruction algorithm using MRI phantom: issues on local geometric accuracy and cortical thickness. *Med Image Comput Comput Assist Interv*. 2006;9(Pt 1):183–190.
49. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. *Neuroimage*. 2002;15:870–878.
50. Xia M, Wang J, He Y. BrainNet Viewer: a network visualization tool for human brain connectomics. *PLoS One*. 2013;8:e68910.
51. Wang J, Wang X, Xia M, Liao X, Evans A, He Y. GREYNET: a graph theoretical network analysis toolbox for imaging connectomics. *Front Hum Neurosci*. 2015;9:386.
52. Abu-Akel A, Shamay-Tsoory S. Neuroanatomical and neurochemical bases of theory of mind. *Neuropsychologia*. 2011;49:2971–2984.
53. Schultz CC, Koch K, Wagner G, et al. Reduced cortical thickness in first episode schizophrenia. *Schizophr Res*. 2010;116:204–209.
54. Kuperberg GR, Broome MR, McGuire PK, et al. Regionally localized thinning of the cerebral cortex in schizophrenia. *Arch Gen Psychiatry*. 2003;60:878–888.
55. Hartberg CB, Lawyer G, Nyman H, et al. Investigating relationships between cortical thickness and cognitive performance in patients with schizophrenia and healthy adults. *Psychiatry Res*. 2010;182:123–133.
56. Byun MS, Kim JS, Jung WH, et al. Regional cortical thinning in subjects with high genetic loading for schizophrenia. *Schizophr Res*. 2012;141:197–203.
57. Rimol LM, Hartberg CB, Nesvåg R, et al. Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. *Biol Psychiatry*. 2010;68:41–50.
58. Park HJ, Lee JD, Chun JW, et al. Cortical surface-based analysis of 18F-FDG PET: measured metabolic abnormalities in schizophrenia are affected by cortical structural abnormalities. *Neuroimage*. 2006;31:1434–1444.
59. Kubota M, Miyata J, Yoshida H, et al. Age-related cortical thinning in schizophrenia. *Schizophr Res*. 2011;125:21–29.
60. Janssen J, Reig S, Alemán Y, et al. Gyrus and sulcus cortical thinning in adolescents with first episode early-onset psychosis. *Biol Psychiatry*. 2009;66:1047–1054.
61. White T, Andreasen NC, Nopoulos P, Magnotta V. Gyrfication abnormalities in childhood- and adolescent-onset schizophrenia. *Biol Psychiatry*. 2003;54:418–426.
62. Nesvåg R, Lawyer G, Varnäs K, et al. Regional thinning of the cerebral cortex in schizophrenia: effects of diagnosis, age and antipsychotic medication. *Schizophr Res*. 2008;98:16–28.
63. Goldman AL, Pezawas L, Mattay VS, et al. Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability. *Arch Gen Psychiatry*. 2009;66:467–477.
64. Jung WH, Kim JS, Jang JH, et al. Cortical thickness reduction in individuals at ultra-high-risk for psychosis. *Schizophr Bull*. 2011;37:839–849.
65. Sigmundsson T, Suckling J, Maier M, et al. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. *Am J Psychiatry*. 2001;158:234–243.
66. Panizzon MS, Fennema-Notestine C, Eyer LT, et al. Distinct genetic influences on cortical surface area and cortical thickness. *Cereb Cortex*. 2009;19:2728–2735.
67. Winkler AM, Kochunov P, Blangero J, et al. Cortical thickness or grey matter volume? The importance of selecting the phenotype for imaging genetics studies. *Neuroimage*. 2010;53:1135–1146.
68. Lyall AE, Shi F, Geng X, et al. Dynamic development of regional cortical thickness and surface area in early childhood. *Cereb Cortex*. 2015;25:2204–2212.
69. Schnack HG, van Haren NE, Brouwer RM, et al. Changes in thickness and surface area of the human cortex and their relationship with intelligence. *Cereb Cortex*. 2015;25:1608–1617.
70. Storsve AB, Fjell AM, Tamnes CK, et al. Differential longitudinal changes in cortical thickness, surface area and volume across the adult life span: regions of accelerating and decelerating change. *J Neurosci*. 2014;34:8488–8498.
71. Evans J, Olm C, McCluskey L, et al. Impaired cognitive flexibility in amyotrophic lateral sclerosis. *Cogn Behav Neurol*. 2015;28:17–26.
72. Frey S, Petrides M. Orbitofrontal cortex and memory formation. *Neuron*. 2002;36:171–176.
73. Bosia M, Riccaboni R, Poletti S. Neurofunctional correlates of theory of mind deficits in schizophrenia. *Curr Top Med Chem*. 2012;12:2284–2302.
74. Pedersen A, Koelkebeck K, Brandt M, et al. Theory of mind in patients with schizophrenia: is mentalizing delayed? *Schizophr Res*. 2012;137:224–229.
75. Das P, Lagopoulos J, Coulston CM, Henderson AF, Malhi GS. Mentalizing impairment in schizophrenia: a functional MRI study. *Schizophr Res*. 2012;134:158–164.
76. Brüne M, Lissek S, Fuchs N, et al. An fMRI study of theory of mind in schizophrenic patients with “passivity” symptoms. *Neuropsychologia*. 2008;46:1992–2001.
77. Benedetti F, Bernasconi A, Bosia M, et al. Functional and structural brain correlates of theory of mind and empathy deficits in schizophrenia. *Schizophr Res*. 2009;114:154–160.
78. Lee J, Quintana J, Nori P, Green MF. Theory of mind in schizophrenia: exploring neural mechanisms of belief attribution. *Soc Neurosci*. 2011;6:569–581.
79. Brüne M, Ozgürdal S, Ansorge N, et al. An fMRI study of “theory of mind” in at-risk states of psychosis: comparison with manifest schizophrenia and healthy controls. *Neuroimage*. 2011;55:329–337.
80. de Achaval D, Villarreal MF, Costanzo EY, et al. Decreased activity in right-hemisphere structures involved in social cognition in siblings discordant for schizophrenia. *Schizophr Res*. 2012;134:171–179.
81. Andreasen NC, Calarge CA, Calage CA, O’Leary DS. Theory of mind and schizophrenia: a positron emission tomography study of medication-free patients. *Schizophr Bull*. 2008;34:708–719.
82. Walter H, Ciaramidaro A, Adenzato M, et al. Dysfunction of the social brain in schizophrenia is modulated by

- intention type: an fMRI study. *Soc Cogn Affect Neurosci*. 2009;4:166–176.
83. Samson D, Apperly IA, Chiavarino C, Humphreys GW. Left temporoparietal junction is necessary for representing someone else's belief. *Nat Neurosci*. 2004;7:499–500.
  84. Doody GA, Götz M, Johnstone EC, Frith CD, Owens DG. Theory of mind and psychoses. *Psychol Med*. 1998;28:397–405.
  85. Lincoln TM, Mehl S, Kesting ML, Rief W. Negative symptoms and social cognition: identifying targets for psychological interventions. *Schizophr Bull*. 2011;37 Suppl 2:S23–S32.
  86. Ventura J, Ered A, Gretchen-Doorly D, Subotnik KL, Horan WP, Helleman GS, Nuechterlein KH. Theory of mind in the early course of schizophrenia: stability, symptom and neurocognitive correlates, and relationship with functioning. *Psychol Med*. 2015:1–13.
  87. Ventura J, Wood RC, Helleman GS. Symptom domains and neurocognitive functioning can help differentiate social cognitive processes in schizophrenia: a meta-analysis. *Schizophr Bull*. 2013;39:102–111.
  88. Brüne M. “Theory of mind” in schizophrenia: a review of the literature. *Schizophr Bull*. 2005;31:21–42.
  89. Ozguven HD, Oner O, Baskak B, Oktem F, Olmez S, Munir K. Theory of mind in schizophrenia and asperger's syndrome: relationship with negative symptoms. *Klinik Psikofarmakol Bulteni*. 2010;20:5–13.
  90. Nummenmaa L, Passamonti L, Rowe J, Engell AD, Calder AJ. Connectivity analysis reveals a cortical network for eye gaze perception. *Cereb Cortex*. 2010;20:1780–1787.
  91. Leitman DI, Wolf DH, Ragland JD, et al. “It's not what you say, but how you say it”: a reciprocal temporo-frontal network for affective prosody. *Front Hum Neurosci*. 2010;4:19.
  92. Tamminga CA, Thaker GK, Buchanan R, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. *Arch Gen Psychiatry*. 1992;49:522–530.
  93. Vercammen A, Knegeting H, Bruggeman R, et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory-verbal hallucinations in schizophrenia: a randomized controlled trial. *Schizophr Res*. 2009;114:172–179.
  94. Kitis O, Ozalay O, Zengin EB, et al. Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non-deficit schizophrenia. *Psychiatry Clin Neurosci*. 2012;66:34–43.